Receive our newsletter – data, insights and analysis delivered to you
July 9, 2009

Amylin Weight Loss Drug Shows Positive Results

Amylin has announced that a 28-week dose-ranging study of pramlintide/metreleptin, a combination treatment for overweight and obese patients, has shown positive results. The phase-II study successfully characterised patients who responded best to treatment, and also provided important in

By cms admin

Amylin has announced that a 28-week dose-ranging study of pramlintide/metreleptin, a combination treatment for overweight and obese patients, has shown positive results.

The phase-II study successfully characterised patients who responded best to treatment, and also provided important information for dose selection.

The phase-II, 28-week, double-blind, placebo-controlled multi-centre study looked at 608 obese or overweight patients. In the overall evaluable study population, all of the pramlintide/metreleptin combination arms achieved more weight loss than a placebo.

The study results confirmed previous phase-II results with the combination therapy, and provide a foundation for the company’s obesity development programme.

Amylin vice-president of corporate development, diabetes and obesity Christian Weyer said that the findings provided valuable data that would inform our clinical and product development strategy.

“Our integrated neurohormonal approach to obesity provides a broad research and development platform that has the potential to yield transformational therapies that address a range of unmet patient needs across the various classes of obesity,” Weyer said.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU